LGALS1 drives chemoresistance in esophageal squamous cell carcinoma by modulating epithelial-mesenchymal transition and tumor immunity

doi:10.3748/wjg.v32.i18.114713

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 18

This Article

(49)

(23)

(0)

(1199)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. May 14, 2026; 32(18): 114713
Published online May 14, 2026. doi: 10.3748/wjg.v32.i18.114713

Full Size Figure Download Figure

Figure 2 Cellchat analysis demonstrates neoadjuvant chemoradiotherapy-mediated development of a pro-inflammatory microenvironment. A: Heatmap illustrating variations in interaction quantity and intensity among distinct cell populations, where red (blue) indicates enhanced (diminished) signaling in neoadjuvant chemoradiotherapy (neoCRT) relative to the surgery group; B: Comparative analysis of interaction frequencies between neoCRT and surgery groups; C: Two-dimensional representation displaying incoming interaction strengths; D: Aggregate communication probability scores for all cellular interactions in both neoCRT and surgery groups; E: Variations in inflammation-associated pathway intensity. NeoCRT: Neoadjuvant chemoradiotherapy; NK: Natural killer.

Citation: Yan QH, Xu CD, Li ZG, Zheng YZ, Wong WS, Liang DC, Yang J, Chang WG, Wang JY. LGALS1 drives chemoresistance in esophageal squamous cell carcinoma by modulating epithelial-mesenchymal transition and tumor immunity. World J Gastroenterol 2026; 32(18): 114713
URL: https://www.wjgnet.com/1007-9327/full/v32/i18/114713.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i18.114713

Yan QH, Xu CD, Li ZG, Zheng YZ, Wong WS, Liang DC, Yang J, Chang WG, Wang JY. LGALS1 drives chemoresistance in esophageal squamous cell carcinoma by modulating epithelial-mesenchymal transition and tumor immunity. World J Gastroenterol 2026; 32(18): 114713 [DOI: 10.3748/wjg.v32.i18.114713]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.